Dynavax Technologies Corporation (NASDAQ:DVAX) Receives Consensus Rating of “Hold” from Brokerages

Dynavax Technologies Corporation (NASDAQ:DVAX) has received an average recommendation of “Hold” from the five brokerages that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $24.3333.

Several research firms have recently commented on DVAX. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. Wall Street Zen raised shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Finally, William Blair downgraded shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th.

Dynavax Technologies Stock Performance

DVAX stock opened at $15.50 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. Dynavax Technologies has a 1 year low of $9.20 and a 1 year high of $15.73. The company has a market cap of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97. The stock’s fifty day moving average price is $14.21 and its 200-day moving average price is $11.75.

Insider Buying and Selling

In related news, COO David F. Novack sold 114,000 shares of Dynavax Technologies stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the transaction, the chief operating officer directly owned 63,344 shares in the company, valued at approximately $990,700.16. The trade was a 64.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.98% of the company’s stock.

Institutional Trading of Dynavax Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Dynavax Technologies by 1.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 1,625 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Dynavax Technologies during the first quarter valued at approximately $180,000. Caxton Associates LLP bought a new position in shares of Dynavax Technologies in the first quarter worth approximately $225,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Dynavax Technologies by 7.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 450,089 shares of the biopharmaceutical company’s stock worth $5,838,000 after purchasing an additional 29,764 shares during the period. Finally, Blair William & Co. IL increased its stake in shares of Dynavax Technologies by 0.3% in the second quarter. Blair William & Co. IL now owns 2,279,647 shares of the biopharmaceutical company’s stock worth $22,614,000 after purchasing an additional 6,940 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.